menu
    • menu
    [{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ SAKK"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantrixil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oasmia Pharmaceutical \/ Oasmia","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ Oasmia"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"Selective mitochondrial electron transfer","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Oasmia Pharmaceutical \/ Lonza","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ Lonza"}]

    Find Clinical Drug Pipeline Developments & Deals by Oasmia Pharmaceutical

    Menu

    Oasmia Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil

                            Details : Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufactur...

                            Brand Name : TRX-E-002-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 21, 2022

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Kazia Therapeutics

                            Deal Size : $46.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kazia Licenses Cantrixil, a Clinical-Stage, First-in-Class Ovarian Cancer Drug Candidate, to Oasmia Pharmaceti...

                            Details : Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.

                            Brand Name : TRE-E-002-1

                            Molecule Type : Small molecule

                            Upfront Cash : $4.0 million

                            March 01, 2021

                            Lead Product(s) : Cantrixil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Kazia Therapeutics

                            Deal Size : $46.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : SAKK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK

                            Details : SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 08, 2020

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : SAKK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oasmia Pharmaceutical Announces Poster Presentation at American Society of Clinical Oncology 2020 Annual Meeti...

                            Details : Data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2020

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oasmia Announces Outcome of Strategic Review to Deliver Long-Term, Profitable Growth as a Specialty Pharma Com...

                            Details : As a result of the review, Oasmia decided to continue the development of Oasmia’s existing pipeline of XR17-based products, including Docecal (docetaxel) in breast and prostate cancers and its combination cancer therapy XR19.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 13, 2020

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Elevar Therapeutics

                            Deal Size : $698.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oasmia Receives Upfront Payment of 20 M USD from Elevar

                            Details : The global strategic partnership deal is signed regarding the commercialization of Oasmia’s anticancer product Apealea®.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            April 21, 2020

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Elevar Therapeutics

                            Deal Size : $698.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Oasmia Pharmaceutical

                            Sweden arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea

                            Details : The partnership between Oasmia and Elevar grants Elevar the exclusive right to commercialize Apealea®, in all global territories, except countries in which Oasmia and its partners are already present.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            March 26, 2020

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth